Iain Ross

ain Ross was appointed to the Board as Non-Executive Chairman in July 2021. He temporarily assumed Executive responsibility in February 2022.

Iain Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years. He held senior commercial roles at Sandoz, Fisons, and Hoffman La Roche before moving into the biotechnology sector where he has been Chairman, CEO, and Director of several international biotechnology companies including Celltech Group plc, Quadrant Healthcare plc, and Redx Pharma plc.

Currently, he is Non-Executive Chairman at Silence Therapeutics PLC (NASDAQ) and Kazia Therapeutics Limited (ASX/NASDAQ), and BiVitrix Therapeutics plc. Mr. Ross is a qualified Chartered Director, Fellow of the Institute of Directors, and Honorary Fellow of Royal Holloway, London University.